Roctavian’s Benefits Sustained for Up to 5 Years in Trial Patients

Roctavian’s Benefits Sustained for Up to 5 Years in Trial Patients

304398

Roctavian’s Benefits Sustained for Up to 5 Years in Trial Patients

Treatment with the investigational gene therapy Roctavian (valoctocogene roxaparvovec) can reduce bleeding frequency and the use of replacement therapies, while maintaining or improving the quality of life of people with severe hemophilia A for up to five years, updated Phase 1/2 trial data show.  “These results represent the longest duration of follow-up from any clinical gene therapy study for severe haemophilia A,” researchers wrote in a new study, which detailed the trial’s results. The study,…

You must be logged in to read/download the full post.